WebJul 21, 2024 · BOSTON, July 21, 2024 /PRNewswire/ -- Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies,... WebFeb 22, 2024 · Press Release Corium's Novel ADHD Medication AZSTARYS® (serdexmethylphenidate and dexmethylphenidate) Shown Safe and Effective in Long-Term Study Published: Feb. 22, 2024 at 8:00 a.m. ET
Corium Receives FDA Approval of ADLARITY® (donepezil transdermal …
WebMar 16, 2024 · In July 2024, Corium launched serdexmethylphenidate and dexmethylphenidate (Azstarys) for the treatment of attention-deficit/hyperactivity disorder in individuals aged 6 years and older, following the FDA approval in March 2024. Reference WebMar 3, 2024 · Boston-based Corium touts its Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) drug as the first and only product containing a d-MPH oral prodrug for treating … cherry grove drug north myrtle beach
Corium Receives FDA Approval of ADLARITY® (donepezil …
WebMar 16, 2024 · CELEBRATION, Fla., March 16, 2024 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), a specialty pharmaceutical … WebOct 11, 2024 · MENLO PARK, Calif., Oct. 11, 2024 -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of … WebOct 11, 2024 · MENLO PARK, Calif., Oct. 11, 2024 -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of … flights from washington dc to bamako